Elastagen Pty Ltd
Elastagen is a clinical stage medical device company that is pioneering Elastatherapy™ using the human protein Elastin to naturally repair and augment the skin. Skin elasticity deteriorates with age due to the progressive loss of the Elastin protein, one of the three key molecules associated with youthful skin. Two of these molecules, Hyaluronic Acid (HA) and Collagen, are already used in aesthetic dermatology, but the potential for Elastin has remained untapped and offers a novel direction in anti-ageing therapy. Elastagen has pioneered the scientific understanding of Elastin and the “elastagenesis” process. Elastagen is also the first company to have succeeded in the scalable commercial GMP compliant manufacture of full length recombinant human Elastin for use in dermatology applications. The Company is currently conducting multiple clinical studies to evaluate the potential of its Elastin formulations to augment the skin and restore elasticity in both cosmetic and medical dermatology applications. Elastagen is located in Sydney, Australia, and is a venture backed private company.
Main business focus/
Listing by sector:
- Medical Devices - Active implantable devices
- Regenerative & Stem Cells
Elastagen has built a strong management team with the necessary skills and experience to successfully develop, validate and commercialise products in the cosmetic and medical dermatology space. Elastagen’s Board of Directors is comprised of individuals with significant experience in financing and managing early stage life science businesses and includes Xavier Yon, who was previously CEO of Galderma; a global leader in ethical dermatology with over 3,000 employees and $ 2 Billion in revenues.
Elastagen is committed to becoming a valued and respected commercial organization developing safe and efficacious products to the highest quality for patients seeking cosmetic and medical dermatology procedures worldwide.
As the world leaders in human Elastin technology, we are the first company to successfully scale up the production of clinical grade GMP manufactured recombinant human tropoelastin, the building block of Elastin. Elastagen operates in compliance with ISO13485 and 21CFR820 and our clinical trial activities are registered under the Australian TGA’s Clinical Trial Notification scheme and run in accordance with the ICH guidelines for Good Clinical Practice.
As we progress our products through the regulatory approval process, we will continue to place a strong emphasis on scientific and clinical excellence and look forward to introducing our promising Elastatherapy™ treatments to the cosmetic and medical dermatology markets worldwide.
The loss and damage to Elastin in the skin is recognised as one of the main causes of the symptoms of ageing. Current treatments which aim to maintain or boost Elastin content in the skin struggle to deliver a measurable effect due to the very low levels at which new Elastin is naturally produced in adult skin. In addition, Elastin or Elastin fragments applied topically to the skin are highly unlikely to penetrate the skin surface to meaningful levels.
Elastagen has produced a range of formulations based on recombinant human tropoelastin, a synthetic version of the building block of Elastin which is identical to that present in normal human skin. These formulations will be utilised in a new generation of skin treatments called Elastatherapy™.
Elastagen’s formulations benefit from a unique approach to combine Elastin with Hyaluronic Acid, providing the ability to replace two of the major components which are lost with ageing and skin damage. Preclinical and clinical studies have demonstrated the safety and potential for this approach to augment and repair the skin in both cosmetic and medical indications.
The Elastin technology was developed through nearly 20 years of research in the laboratories of Professor Anthony Weiss at the University of Sydney. Since licensing the technology, Elastagen has worked extensively with researchers, clinicians and product consultants in Europe, North America and Australia to further develop and refine the technology. Elastagen has an extensive intellectual property portfolio covering the production, formulation and application of Elastin.
Elastagen welcomes expressions of interest from commercial partners with sales and marketing capabilities and an active interest in aesthetic and medical dermatology applications.
|Contact person||Dr Robert Daniels|
|Address||Australian Technology Park, Suit 145 National Innovation Centre,|
|State||New South Wales|
|Phone||02 9209 4054|